GLP-1 Crackdown: What the FDA Really Means & Why Compounding Still Matters
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
GLP-1 Crackdown: What the FDA Really Means & Why Compounding Still Matters
-
Narrated by:
-
By:
About this listen
There’s been a lot of noise lately around semaglutide, tirzepatide, and other GLP-1 medications—especially as the FDA cracks down on certain compounded versions. But what’s really going on? And what should patients and providers know?
In this solo episode, I unpack the truth behind the headlines. We’ll clarify what GLP-1 medications actually are (hint: they’re not insulin), why they’re in such high demand, and how compounding pharmacies legally stepped in during national shortages. I’ll also break down the difference between 503A and 503B pharmacies and share how to spot quality in compounded meds.
Whether you’re a patient, provider, or pharmacy pro, this episode clears the fog around GLP-1s and gives you real tools to stay informed.
No reviews yet